The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3′ non-coding region of the genome  by Engel, Amber R. et al.
Virology 405 (2010) 243–252
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roThe neurovirulence and neuroinvasiveness of chimeric tick-borne
encephalitis/dengue virus can be attenuated by introducing deﬁned mutations into
the envelope and NS5 protein genes and the 3′ non-coding region of the genome
Amber R. Engel, Alexander A. Rumyantsev 1, Olga A. Maximova, James M. Speicher, Brian Heiss,
Brian R. Murphy, Alexander G. Pletnev ⁎
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA⁎ Corresponding author. Building 33, Room 3W10A,
3203, Bethesda, MD 20892, USA. Fax: +1 301 480 0501
E-mail addresses: engelam@mail.nih.gov (A.R. Engel
alexander.rumyantsev@sanoﬁpasteur.com (A.A. Rumyan
maximovao@mail.nih.gov (O.A. Maximova), jspeicher@
heissb@niaid.nih.gov (B. Heiss), bmurphy@niaid.nih.gov
apletnev@niaid.nih.gov (A.G. Pletnev).
1 Present address: Sanoﬁ Pasteur, 38 Sydney St., Cam
0042-6822/$ – see front matter. Published by Elsevier
doi:10.1016/j.virol.2010.06.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 April 2010
Returned to author for revision 17 May 2010
Accepted 7 June 2010





NeurovirulenceTick-borne encephalitis (TBE) is a severe disease affecting thousands of people throughout Eurasia. Despite
the use of formalin-inactivated vaccines in endemic areas, an increasing incidence of TBE emphasizes the
need for an alternative vaccine that will induce a more durable immunity against TBE virus (TBEV). The
chimeric attenuated virus vaccine candidate containing the structural protein genes of TBEV on a dengue
virus genetic background (TBEV/DEN4) retains a high level of neurovirulence in both mice and monkeys.
Therefore, attenuating mutations were introduced into the envelope (E315) and NS5 (NS5654,655) proteins,
and into the 3′ non-coding region (Δ30) of TBEV/DEN4. The variant that contained all three mutations
(vΔ30/E315/NS5654,655) was signiﬁcantly attenuated for neuroinvasiveness and neurovirulence and
displayed a reduced level of replication and virus-induced histopathology in the brains of mice. The high
level of safety in the central nervous system indicates that vΔ30/E315/NS5654,655 should be further evaluated
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Tick-borne encephalitis (TBE) is a severe neurological disease
caused by several antigenically related RNA viruses within the tick-
borne encephalitis virus (TBEV) serocomplex of the Flaviviridae family
(Lindenbach et al., 2007). Viruses in the TBEV complex are endemic to
Europe, Asia, and North America and include the European, Siberian,
and Far Eastern subtypes of TBEV as well as Kyasanur forest disease,
Langat (LGT), louping ill (LI), Omsk hemorrhagic fever, and Powassan
viruses. TBEV is transmitted in nature to various mammals through
the bite of an infected tick. Humans serve as incidental hosts and can
also become infected by ingesting unpasteurized milk products
obtained from infected ruminants or by accidental exposure via
aerosol (Gritsun et al., 2003).
TBEV creates a signiﬁcant public health burden in endemic areas
due to neurological disease in humans, leading to severe, long-term
neurological complications with up to 30% mortality (Gritsun et al.,
2003). Symptoms of TBE range from non-speciﬁc febrile illness tomeningoencephalitis, although the majority of TBEV infections
remain subclinical. However, more than 10,000 hospitalized cases of
TBEV are reported annually in Europe and Russia, indicating a much
higher incidence of infection than is generally recognized (Suss,
2003). Furthermore, there has been an increase in the number of TBE
cases during the last 20 years, likely due to many factors including
climate change, social and economic changes in land use, and low
vaccination coverage rates in endemic regions (Kunze, 2006;
Randolph, 2008).
The TBEV genome is a positive-sense single-stranded RNA that is
approximately 11 kb in length and contains 5′ and 3′ non-coding
regions (NCR) ﬂanking a single open reading frame that encodes a
polyprotein. The polyprotein is processed by viral and cellular
proteases into three structural proteins (capsid (C), premembrane
(prM), and envelope (E)) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Lindenbach et al., 2007). The
non-structural proteins regulate virus RNA replication and translation
and attenuate host antiviral responses, whereas the structural
proteins mediate virus attachment, membrane fusion, virus assembly,
and elicit protective immunity in the host (Diamond, 2009;
Lindenbach et al., 2007; Robertson et al., 2009).
Despite several attempts over the last 60 years to develop a safe,
efﬁcacious live attenuated virus vaccine against TBEV (Gritsun et al.,
2003), it has been difﬁcult to derive one that is satisfactorily
attenuated for the central nervous system (CNS) of humans. However,
four formalin-inactivated TBEV vaccines are licensed for use in
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Encepur®, derived from Central European TBEV strains Neudoerﬂ
and K23, respectively; Institute of Poliomyelitis and Viral Encephalit-
ides TBEV vaccine and Microgen Encevir®, derived from Far Eastern
strains Sofjin and 205, respectively) (Barrett et al., 2004; Leonova and
Pavlenko, 2009). Although protective levels of neutralizing antibodies
in humans are induced after primary immunization with three doses
of the inactivated virus vaccine, booster immunizations are required
every 3 to 5 years since neutralizing antibody titers decline over time
and with age (Barrett et al., 2004). Nevertheless, extensive TBEV
vaccination in Austria has demonstrated that use of the inactivated
TBEV vaccine in endemic areas results in a dramatic decline of TBE
incidence (Barrett et al., 2004; Kunze, 2006), indicating a high level of
efﬁcacy with the inactivated virus vaccine. Although TBEV vaccination
in Austria has been highly successful, several practical concerns have
arisen with use of the inactivated virus vaccines, including the long
schedule of primary immunization, the need for repeated booster
vaccinations due to the relatively short duration of immunity, and the
high cost of manufacture, all of which contribute to the relatively high
cost of immunization. Furthermore, the lower immune responsive-
ness in the elderly and the rare occurrence of severe TBE disease due
to incomplete protection of vaccinees in endemic areas are also of
concern with the inactivated virus vaccines (Andersson et al., 2010;
Bender et al., 2004; Brauchli et al., 2008; Kleiter et al., 2006; Plisek
et al., 2008). Use of a live attenuated TBEV vaccine that induces long-
lasting protective immunity is the most likely alternative approach to
prevent TBE, since one or two doses of live attenuated yellow fever
(YF) virus 17D vaccine (Monath, 2005) and Japanese encephalitis (JE)
virus SA 14-14-2 vaccine (Halstead and Tsai, 2004) have been shown
to provide immunity for at least 10 years.
In an effort to develop an efﬁcacious live attenuated vaccine
against TBE, a chimeric TBEV/DEN4 virus was previously generated by
replacing the prM and E protein genes of non-neuroinvasive,
mosquito-borne dengue type 4 (DEN4) virus with the corresponding
genes of highly virulent Far Eastern TBEV strain Sofjin (Pletnev et al.,
1992). Although TBEV/DEN4 exhibits greatly reduced neuroinvasive-
ness in immunocompetent mice compared to the TBEV parental virus
and provides complete protection against lethal challenge with TBEV
strain Sofjin, it retains neuroinvasiveness in immunodeﬁcient mice
and a substantial level of neurovirulence in suckling mice (Pletnev
et al., 1992, 1993; Rumyantsev et al., 2006a). Therefore, in an effort to
satisfactorily attenuate TBEV/DEN4 for neuroinvasiveness and neu-
rovirulence, the chimera was modiﬁed by introducing a genetically
stable 30 nucleotide deletion (Δ30) in the 3′ NCR of the DEN4 portion
of the genome since this mutation was previously shown to attenuate
DEN1 and DEN4 viruses as well as chimeric West Nile, St. Louis
encephalitis, and DEN2 (WN/DEN4, SLE/DEN4, DEN2/DEN4) vaccine
candidates in mice, monkeys, and/or humans (Blaney et al., 2008;
Durbin et al., 2001, 2006a,b; Pletnev et al., 2006; Whitehead et al.,
2003). Although introduction of the Δ30 mutation into the TBEV/
DEN4 genome has a signiﬁcant attenuating effect on neuroinvasive-
ness in immunodeﬁcient mice and on the level of viremia in rhesus
monkeys, TBEV/DEN4Δ30 still retains a high level of neurovirulence
in suckling mice (Rumyantsev et al., 2006a) and a moderate level of
neurovirulence in rhesus monkeys (Maximova et al., 2008). Hence, a
further reduction in the level of neurovirulence of the chimeric TBEV/
DEN4 or TBEV/DEN4Δ30 virus was needed before it could be con-
sidered for evaluation in humans.
In the present study, further attenuation of the neuroinvasiveness
and neurovirulence of TBEV/DEN4 and TBEV/DEN4Δ30 was sought
by introducing amino acid substitutions that had previously been
shown to reduce ﬂavivirus replication in mouse brain or in neuronal
cell lines (Hanley et al., 2002; Rumyantsev et al., 2006b). Rumyantsev
et al. (2006b) demonstrated that a single Lys→Glu substitution in the
E protein at position 315 (E315) in LGT virus reduces neuroinvasive-
ness in immunodeﬁcient mice and decreases its replication in humanand murine neuronal cells. In addition, Hanley et al. (2002) demon-
strated that several paired charge-to-alanine substitutions in the NS5
polymeraseprotein, includinganAspArg→AlaAla substitution inNS5at
positions 654 and 655 (NS5654,655), attenuate DEN4 virus neuroviru-
lence for suckling mice. In the current studies, the substitutions at
residues E315 and/or NS5654,655 were introduced into either the TBEV/
DEN4 or TBEV/DEN4Δ30 genome and the phenotypes of the resulting
viruses were evaluated in vitro and in vivo. The mutant viruses were
attenuated for replication in cell culture and attenuated for neuroinva-
siveness and neurovirulence in mice compared to TBEV/DEN4 and
TBEV/DEN4Δ30 viruses.
Results
Derivation of chimeric TBEV/DEN4 and TBEV/DEN4Δ30 mutant viruses
Eight chimeric viruseswere used in these studies. Two viruses, TBEV/
DEN4 and TBEV/DEN4Δ30, have been described previously (Pletnev et
al., 1992; Rumyantsev et al., 2006a). Chimeric TBEV/DEN4 virus contains
the structural prM and E protein genes of the Far Eastern TBEV strain
Sofjin aswell as the remaining capsid andnon-structural protein genes of
DEN4 virus, whereas TBEV/DEN4Δ30 also contains the Δ30 deletion
within the 3′ NCR of the DEN4 portion of the genome. Since both TBEV/
DEN4 and TBEV/DEN4Δ30 viruses retain substantial neurovirulence in
suckling mice (Rumyantsev et al., 2006a), two sets of amino acid
substitutions within the E (Lys315→Asp) and NS5 (AspArg654,655→
AlaAla) protein genes were introduced, singly or in combination, into
either the TBEV/DEN4 or TBEV/DEN4Δ30 infectious cDNA clone in order
to further attenuate the viruses. Three new chimeric TBEV/DEN4 virus
mutants (designated as vE315, vNS5654,655, and vE315/NS5654,655) and
three new TBEV/DEN4Δ30 virus mutants (designated as vΔ30/E315,
vΔ30/NS5654,655, and vΔ30/E315/NS5654,655) containing these substitu-
tions were recovered from Vero cells and biologically cloned by terminal
dilution. Sequence analysis encompassing the regions of thesemutations
revealed that all recovered viruses contained the desired mutations.
Mutant viruses replicated to titers of at least 106.4 PFU/mlwhenampliﬁed
in Vero cells at 32 °C, a temperature that was considered permissive for
viral replication based on previous studies with LGT and DEN4 viruses
containing the E315 and NS5654,655 amino acid substitutions, respectively
(Hanley et al., 2002; Rumyantsev et al., 2006b).
In vitro characterization of chimeric viruses
The temperature sensitivity (ts) phenotypes of chimeric TBEV/
DEN4 and TBEV/DEN4Δ30 mutant viruses were determined by
titration of each virus in simian Vero cells and in human neuronal
SH-SY5Y or LN-18 cells at various temperatures since previous studies
with LGT and DEN4 viruses have shown that a ts phenotype in cell
culture is often associated with attenuation in vivo (Hanley et al.,
2002; Rumyantsev et al., 2006a,b). TBEV/DEN4, TBEV/DEN4Δ30, and
vE315 viruses were not ts in any of the cell lines examined (Table 1).
However, mutating the NS5654,655 residues, which are ts in the
parental DEN4 mutant virus (Hanley et al., 2002), resulted in a ts
phenotype for the TBEV/DEN4Δ30 virus. Although the E315 and Δ30
mutations did not confer ts phenotypes themselves, combining them
with the NS5654,655 mutation greatly increased the level of temper-
ature sensitivity (Table 1). Such tsmutant viruses would be expected
to exhibit an attenuation phenotype in mice. For example, the triple
mutant virus, vΔ30/E315/NS5654,655, was highly restricted in its
replication at 37 °C and 39 °C in each cell line, suggesting that it
should be restricted for replication in the brains of mice, which have a
core body temperature of 37 °C.
Since small plaque (sp) phenotype in cell culture has also been
associated with attenuation in vivo (Rumyantsev et al., 2006a,b;
Wright et al., 2008), this characteristic was separately evaluated in
Vero cells. Although none of the three individual mutations affected
Table 1
Efﬁciency of plaque formation of TBEV/DEN4- and TBEV/DEN4Δ30-derived viruses in Vero, SH-SY5Y, and LN-18 cell lines at permissive and restrictive temperatures.
Virus Virus titer (log10 PFU/ml) at the indicated temperature (°C)
Vero SH-SY5Y LN-18
32 35 37 39 Δa tsb spc 32 35 37 39 Δ ts 32 35 37 39 Δ ts
TBEV/DEN4 6.4 6.4 6.1 6.0 0.4 − − 6.4 6.4 6.1 6.1 0.3 − 5.7 5.5 5.6 5.3 0.4 −
vE315 6.8 6.7 6.4 6.0 0.8 − − 7.3 7.1 6.5 6.0 1.3 − 6.0 6.3 5.8 4.4 1.6 −
vNS5654,655 6.9 6.9 6.8 5.2 1.7 − − 7.0 6.7 6.9 6.0 1.0 − 6.0 6.1 6.0 b1.7 N4.3 +
vE315/NS5654,655 6.5 5.6 4.0 b1.7 N4.8 + + 7.0 6.3 6.0 b1.7 N5.3 + 5.3 4.3 2.0 b1.7 N3.6 +
TBEV/DEN4Δ30 7.8 7.5 7.1 6.0 1.8 − − 7.8 7.9 7.3 6.5 1.3 − 6.9 6.7 6.3 5.0 1.9 −
vΔ30/E315 6.7 6.7 6.3 5.7 1.0 − + 6.8 6.5 6.4 5.8 1.0 − 4.8 5.3 4.9 3.0 1.8 −
vΔ30/NS5654,655 7.4 6.9 4.0 2.8 4.6 + + 7.2 6.7 6.7 2.6 4.6 + 6.5 6.1 4.0 1.3 5.2 +
vΔ30/E315/NS5654,655 6.6 5.8 3.0 b1.0 N5.6 + + 6.4 6.0 3.7 b1.0 N5.4 + 4.0 3.0 2.0 b1.0 N3.0 −
a Reduction in virus titer at 39 °C compared to the virus titer at 32 °C.
b Amutant virus was deﬁned as having a ts phenotype if its shutoff temperature was≤39 °C. The shutoff temperature for plaque formation was deﬁned as the lowest temperature
at which the reduction in virus titer at a restrictive temperature compared to its titer at 32 °C was 100-fold greater than the reduction in parental virus titer between the same two
temperatures (formula for calculating ts phenotype: ≥2.0 log10 PFU/ml=(Titer32 °C−Titer39 °C)Chimeric virus−(Titer32 °C−Titer39 °C)Parental virus). Values in bold indicate ≥2.0 log10
PFU/ml reduction in titer at the indicated temperature.
c The sp phenotype was deﬁned as virus mean plaque diameter ≤50% of TBEV/DEN4 or TBEV/DEN4Δ30 virus on Vero cells at 32 °C. Mean plaque diameter of TBEV/DEN4 and
TBEV/DEN4Δ30 following a 6-day incubation at 32 °C was 1 mm.
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or more of these mutations acquired the sp phenotype (Table 1). Thus,
vΔ30/E315/NS5654,655 was highly attenuated in vitro as shown by ts
and sp phenotypes, indicating that it may be attenuated in vivo.Neurovirulence of chimeric viruses in suckling mice
The neurovirulence of TBEV/DEN4 and TBEV/DEN4Δ30 mutant
viruses was evaluated in 3-day-old mice by estimating LD50 values
after intracerebral (IC) inoculation. Mice of this age were used
because they are a highly sensitive model for evaluation of ﬂavivirus
neurovirulence. Consistent with previous observations (Rumyantsev
et al., 2006a), introduction of the Δ30 deletion into the TBEV/DEN4
genome did not alter the virus LD50 or the average survival time (AST)
after IC inoculation (Table 2). However, introduction of the E315 or
NS5654,655 mutation into TBEV/DEN4 increased the LD50 of the
resulting mutant viruses by 8- to 20-fold, respectively, while co-
introduction of both substitutions signiﬁcantly increased the LD50 by
51-fold (pb0.05) (Table 2). Furthermore, the AST of these mice
increased from 7.4 days to 8.6, 12.2, and N21 days for viruses
containing the E315, NS5654,655, and E315/NS5654,655 mutations,
respectively. These ﬁndings indicate that the E315 and NS5654,655
mutations, individually or in combination, decreased the neuroviru-
lence of TBEV/DEN4 for 3-day-old mice.Table 2
Neurovirulence of TBEV/DEN4- and TBEV/DEN4Δ30-derived viruses in 3-day-old
Swiss Webster mice.
Virus LD50 (PFU)a LD50 fold reductionb AST (days)c
TBEV/DEN4 0.8 — 7.4
vE315 6.6 8 8.6
vNS5654,655 16.2 20 12.2
vE315/NS5654,655 40.8⁎ 51 N21
TBEV/DEN4Δ30 1.0 — 7.0
vΔ30/E315 4.1 4 11.9
vΔ30/NS5654,655 40.7⁎ 41 16.6
vΔ30/E315/NS5654,655 487⁎ 487 N21
⁎ Statistically signiﬁcant differences (pb0.05, nominal logistic ﬁt for survival)
between LD50 values of parental (TBEV/DEN4 and TBEV/DEN4Δ30) andmutant viruses.
a Multiple litters of approximately 10 mice (range 9–16) were inoculated IC with 10-
fold serial dilutions of virus ranging from 0.1 to 10 PFU of TBEV/DEN4 or TBEV/
DEN4Δ30 and from 1 to 104 PFU for mutant viruses to determine their LD50 values. Mice
were monitored for signs of encephalitis for 21 days and moribund mice were
euthanized.
b Fold-reduction of neurovirulence of mutant virus compared to TBEV/DEN4 or
TBEV/DEN4Δ30 parental viruses.
c Average survival times (AST) of mice following IC inoculation with 10 PFU of virus.A similar effect on neurovirulence was observedwhen the E315 and
NS5654,655 mutations were introduced into the TBEV/DEN4Δ30
parental virus. Although moderate decreases in neurovirulence were
noted for TBEV/DEN4-derived viruses, more substantial decreases in
neurovirulence were observed for TBEV/DEN4Δ30 mutant viruses
containing either individual substitutions at E315 or NS5654,655, or both
substitutions (E315/NS5654,655), as demonstrated by 4- to 487-fold
increases in LD50 values (Table 2). In addition, an increase of the AST
(11.9, 16.6, or N21 days) was observed with TBEV/DEN4Δ30 viruses
containing E315, NS5654,655, or E315/NS5654,655 mutations, respectively.
Introduction of NS5654,655 or E315/NS5654,655 into TBEV/DEN4Δ30
attenuated the virus to a greater extent than E315, NS5654,655, or Δ30
individually. Additionally, introducing NS5654,655 or both E315 and
NS5654,655 substitutions signiﬁcantly attenuated TBEV/DEN4Δ30
(pb0.05) (Table 2). Although the Δ30 mutation did not seem to
alter neurovirulence on its own, its introduction together with E315
and/or NS5654,655 into TBEV/DEN4 had an additive attenuating effect,
as shown by greater increases in LD50 and AST compared to those
observed for viruses that contained the individual mutations.
Genomic sequence of the TBEV/DEN4Δ30 mutant viruses
Since TBEV/DEN4Δ30-derived mutant viruses were more attenu-
ated in tissue culture and in suckling mice compared to the TBEV/
DEN4-derivedmutant viruses, theywere suggested to be safer vaccine
candidates than the TBEV/DEN4 viruses. Therefore, the TBEV/
DEN4Δ30-derived viruses were selected for additional characteriza-
tion. The entire consensus sequence was ﬁrst determined for TBEV/
DEN4, TBEV/DEN4Δ30, and all TBEV/DEN4Δ30 mutant viruses.
Several adventitious mutations, which are common for recombinant
DEN4-based ﬂaviviruses recovered and passaged in Vero cell culture,
occurred among the mutant viruses (Blaney et al., 2002, 2003, 2008;
Pletnev et al., 2006; Rumyantsev et al., 2006a). In addition to the Δ30
deletion, the consensus sequence of the biologically cloned TBEV/
DEN4Δ30 differed from that of TBEV/DEN4 by three amino
acid substitutions (prM Asp54→Tyr, NS3 Ile123→Thr, and NS4B
Leu112→Ser), as described previously (Rumyantsev et al., 2006a).
However, despite these genetic differences, both viruses replicated
efﬁciently in neuronal cells and were also highly neurovirulent for
suckling mice, as shown by comparable LD50 values. These data
indicate that the adventitious mutations had no detectable effect on
the observed properties of TBEV/DEN4Δ30 virus in vitro and in vivo.
Adventitious mutations also occurred in all three TBEV/DEN4Δ30
mutant viruses (Table 3). Four adventitious mutations occurred in
vΔ30/E315 virus, including three that encoded amino acid substitu-
tions (prM Asp54→Tyr, NS2A Ile198→Leu, and NS4B Thr105→ Ile).
Table 3
Mutations identiﬁed in TBEV/DEN4Δ30 and its derivative viruses after recovery and





Gene Amino acid change
and positionb,c
TBEV/DEN4Δ30 618 G→U prM Asp54→Tyr
4724 U→C NS3 silent
4906 U→C NS3 Ile123→Thr
7177 U→C NS4B Leu112→Ser
vΔ30/E315 618 G→U prM Asp54→Tyr
1893 A→G E Lys315→Asp
1895 A→C
4086 A→C NS2A Ile198→Leu
7156 C→U NS4B Thr105→ Ile
7626 C→U NS5 silent
vΔ30/NS5654,655 1953 A→G E Thr335→Ala
4821 G→A NS3 Val95→ Ile
6959 A→G NS4B silent
7352 A→G NS4B silent
7610 G→A NS5 silent
9538 A→C NS5 Asp654→Ala
9539 C→A
9540 A→G NS5 Arg655→Ala
9541 G→C
vΔ30/E315/NS5654,655 1668 C→U E Arg240→Trp
1893 A→G E Lys315→Asp
1895 A→C
7178 A→U NS4B Leu112→Phe
9538 A→C NS5 Asp654→Ala
9539 C→A
9540 A→G NS5 Arg655→Ala
9541 G→C
a Numbering of nucleotide positions reﬂects relative nucleotide positions within the
TBEV/DEN4Δ30 chimeric virus (GenBank accession no. FJ828987).
b Nucleotide and amino acid sequence changes that occurred during the recovery of
virus from the cDNA clone. Bold changes are mutated positions that have been
introduced by site-directed mutagenesis during these studies.
c Amino acid position is calculated from the ﬁrst codon of each individual protein
coding region.
Fig. 1. Virus replication kinetics of TBEV/DEN4Δ30 or its derived mutants in the brains
of suckling mice. Litters of 5-day-old Swiss mice were inoculated IC with 103 PFU of
virus. Brains of at least three mice per group were harvested on odd days post-
inoculation and quantitated for virus titers by immunofocus assay on Vero cells; the
mean virus replication titers±SE are shown. Asterisks indicate that the vΔ30/E315/
NS5654,655 mutant replicates signiﬁcantly lower than the remaining viruses on the
indicated day (unpaired t test or one-way ANOVA followed by Tukey post hoc test,
pb0.05). The § indicates that only two mouse brains were harvested in the vΔ30/E315
group on day 9, as they were the only remaining animals in the group. The limit of
detection was 2.0 log10 PFU/g. Lines end at the day when all animals succumbed to
infection, with the exception of day 21 when the experiment was terminated.
Table 4
Genetic stability of introduced mutations in TBEV/DEN4Δ30 mutant viruses present in








vΔ30/E315 8 10 0/10 0/10 —
9 2 0/2 0/2 —
vΔ30/NS5654,655 13 7 0/7 — 0/7
vΔ30/E315/NS5654,655 15 2 0/2 0/2 0/2
17 4 0/4 0/4 0/4
a Five-day-old mice were inoculated IC with 103 PFU of indicated virus.
b Brains of mice were harvested on indicated day, and virus RNA was isolated from
brain homogenate to determine virus genomic sequence.
c The virus genome regions encompassing the introduced Δ30, E315, or NS5654,655
mutations were directly sequenced from brain homogenates to determine stability of
the mutations. Dashed lines indicate that no mutation was originally introduced at this
position.
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identiﬁed in other viruses as Vero cell adaptation mutations (Blaney
et al., 2001, 2002, 2003, 2008; Rumyantsev et al., 2006a). Five
adventitious mutations were identiﬁed throughout the consensus
sequence of vΔ30/NS5654,655 virus, two of which encoded amino acid
substitutions (E Thr335→Ala and NS3 Val95→ Ile). The triple mutant
virus, vΔ30/E315/NS5654,655, contained an additional two amino acid
substitutions (E Arg240→Trp and NS4B L112→Phe) compared to
TBEV/DEN4Δ30 virus, of which NS4B112 has been previously
identiﬁed as a Vero cell adaptation mutation (Blaney et al., 2001,
2002, 2003, 2008; Rumyantsev et al., 2006a). Although adventitious
mutations occurred in all TBEV/DEN4Δ30-derived viruses, they did
not appear to affect the virus phenotype as the introduced mutations
demonstrated the same pattern of attenuation, regardless of whether
they were introduced in the TBEV/DEN4 or TBEV/DEN4Δ30 backbone
(i.e., E315NNS5654,655NE315/NS5654,655).
Replication of TBEV/DEN4Δ30 mutant viruses in suckling mouse brain
Since TBEV/DEN4Δ30-based mutant viruses were more attenuat-
ed for neurovirulence in mice compared to the TBEV/DEN4
derivatives, the replication kinetics and genetic stability of the viruses
were evaluated in the brains of suckling mice (Fig. 1). Following IC
inoculation with 103 PFU of virus, TBEV/DEN4Δ30 rapidly reached
high titers (107.6 PFU/g) in mice by day 5 and caused paralysis or
death on day 7. However, the mutant viruses replicated to lower titers
and achieved peak virus titers later than TBEV/DEN4Δ30. vΔ30/E315
and vΔ30/NS5654,655 demonstrated 25- to 32-fold decreases in their
peak titers compared to TBEV/DEN4Δ30. vΔ30/E315/NS5654,655 was
the most attenuated in suckling mouse brains, as its peak titer was
approximately 20,000-fold lower than TBEV/DEN4Δ30. Furthermore,the triple mutant virus replicated signiﬁcantly lower in the brains of
suckling mice than all viruses compared on days 3, 5, 7, 11, and 13
(pb0.05).
To investigate genetic stability of the introduced mutations in the
TBEV/DEN4Δ30-derived mutant viruses, genomic sequence of the
virus RNA present in the brains of mice was obtained for all viruses at
the endpoint of study (paralysis or on the last day with detectable
virus) by directly sequencing RT-PCR cDNA fragments without
passage of the virus in cell culture (Table 4). Sequence analysis of
vΔ30/E315 from 12 infectedmice on days 8 and 9 and vΔ30/NS5654,655
from seven infectedmice on day 13 demonstrated that the engineered
mutations at E315, NS5654,655, and Δ30 were stable (Table 4).
Furthermore, all virus genomes from six brains harvested on days
15 and 17 from mice inoculated with the triple mutant virus (vΔ30/
E315/NS5654,655) were found to contain all three sets of introduced
mutations. Only one mouse was paralyzed in the triple mutant group
(day 17); however, all introduced mutations were stable in the virus
present in the brain of this animal.
Neuroinvasiveness of chimeric viruses in immunodeﬁcient mice
Since parental TBEV/DEN4 lost its ability to spread from a
peripheral site of inoculation to the CNS in immunocompetent mice
(Pletnev et al., 1993), we investigated the neuroinvasive properties of
our modiﬁed TBEV/DEN4Δ30 viruses in immunodeﬁcient mice.
Table 5
Neuroinvasiveness of TBEV/DEN4, TBEV/DEN4Δ30, and TBEV/DEN4Δ30 mutant
derivatives in immunodeﬁcient SCID mice.
Virus Dose (PFU) AST (day) No. moribund/
No. tested (%)
TBEV/DEN4 105 23 6/10 (60)
TBEV/DEN4Δ30 105 22 10/56 (18)⁎
vΔ30/E315 105 32 3/33 (9)⁎
vΔ30/NS5654,655 105 N49 0/33 (0)⁎,§
vΔ30/E315/NS5654,655 105 N49 0/41 (0)⁎,§
⁎ All TBEV/DEN4Δ30 derivatives were signiﬁcantly different from TBEV/DEN4
(pb0.05, Kaplan–Meier survival curve followed by Tukey post hoc test).
§ vΔ30/NS5654,655 and vΔ30/E315/NS5654,655 were signiﬁcantly different from TBEV/
DEN4Δ30 (pb0.05, Kaplan–Meier survival followed by Tukey post hoc test).
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PFU of chimeric virus and were assessed for AST, morbidity, and virus
replication in the brain. Although introduction of the Δ30 deletion
into TBEV/DEN4 has no effect on neurovirulence, a decrease in
neuroinvasiveness was observed for TBEV/DEN4Δ30 virus, as shown
by a signiﬁcant reduction in morbidity (from 60% to 18%) of mice
compared to that of TBEV/DEN4 (pb0.05) (Table 5). Since these
ﬁndings are consistent with our previous observations (Rumyantsev
et al., 2006a), we investigated the ability of Δ30 in combination with
E315 and/or NS5654,655 substitutions to further reduce neuroinvasive-
ness. Although the combination of E315 with Δ30 increased the AST
and decreased the morbidity compared to TBEV/DEN4Δ30, the dif-
ference was not signiﬁcant. However, introduction of NS5654,655 or the
combination of E315/NS5654,655 mutations into the TBEV/DEN4Δ30
genome greatly diminished (pb0.05) the ability of the chimeric virus
to invade the CNS from a peripheral site of inoculation and cause
neurological disease (Table 5).
We next investigated the ability of the TBEV/DEN4Δ30 mutant
viruses to invade and replicate in the CNS after peripheral inoculation.
Adult immunodeﬁcient SCID mice were inoculated IP with 105 PFU of
virus, and brains were harvested on odd days post-infection. TBEV/
DEN4 replicated in the brains between 106.5 and 108.5 PFU/g on days 7
to 21 and was signiﬁcantly different from all viruses on all days
(pb0.05), except for TBEV/DEN4Δ30 on days 17 and 21 (Fig. 2).
Although TBEV/DEN4Δ30 virus replication was not detected in
peripheral tissues, such as the spleen and liver (data not shown),
virus was detected in the brain on days 11 to 21 (102.1 to 106.6 PFU/g),
and the mean peak virus titer (106.6 PFU/g) was observed on day 15
(Fig. 2). Since TBEV/DEN4Δ30 virus demonstrated the highest titersFig. 2. Replication of TBEV/DEN4, TBEV/DEN4Δ30, and TBEV/DEN4Δ30 mutant derivatives i
the indicated days, three mouse brains per group were harvested, and the virus titer of each
virus titers are indicated±SE. Asterisks indicate that virus replication on indicated day is sign
by Tukey post hoc test, pb0.05). Horizontal dashed line indicates limit of detection (1.7 logbetween days 13 and 19 pi, these days were chosen to harvest brains
from SCID mice infected with the TBEV/DEN4Δ30 mutant derivatives
in order to assess the ability of these viruses to invade and replicate in
the CNS from a peripheral site of inoculation. Replication of the
mutant viruses was signiﬁcantly impaired (pb0.05), as infectious
virus was not recovered from the brains of SCID mice on any of these
days following IP inoculation with vΔ30/E315, vΔ30/NS5654,655, or
vΔ30/E315/NS5654,655 (Fig. 2). These studies conﬁrm the highly
reduced neuroinvasive phenotype of the mutant viruses and clearly
demonstrate that the introduction of both E315 and NS5654,655
mutations into the TBEV/DEN4Δ30 genome attenuates the chimeric
virus in mice for both neuroinvasiveness and neurovirulence to a
greater extent than either mutation alone.
Neuropathology induced by chimeric viruses in mice
Since vΔ30/E315/NS5654,655 demonstrated the greatest attenuation
in both suckling and immunodeﬁcient mice, we were interested in
further investigating the safety of the triple mutant virus for the CNS;
therefore, the ability of this virus to induce neuropathology in mice
was assessed. Brain histopathology was analyzed in groups of three
adultmice inoculated ICwith 104 PFU of TBEV/DEN4, TBEV/DEN4Δ30,
or vΔ30/E315/NS5654,655 viruses on day 6, the time at which mice
inoculatedwith TBEV/DEN4 virus succumbed to infection. At this time
point, a high level of virus replication (mean virus titer 104.8 PFU/g)
was detected in the brains of TBEV/DEN4-infectedmice,whereas virus
titers were 32-fold lower (mean virus titer 103.3 PFU/g) in mice
inoculated with TBEV/DEN4Δ30. The mean virus titer (101.7 PFU/g)
observed in the brains of mice infected with vΔ30/E315/NS5654,655
virus was approximately 40- to 1259-fold lower than that observed
with TBEV/DEN4Δ30 and TBEV/DEN4, respectively.
Brain histopathology correlated well with the level of virus
replication, as the most severe and widespread histopathology
(including perivascular and parenchymal mononuclear inﬂammatory
cell inﬁltration, microglial proliferation, and neuronal degeneration)
was observed in mice infected with the parental TBEV/DEN4 virus
(Figs. 3A, D, and G). TBEV/DEN4Δ30 induced less severe neuroin-
ﬂammation (Figs. 3B, E, and H) compared to the parental TBEV/DEN4
virus, whereas virus-associated inﬂammatory changes were not
observed in the brains of mice inoculated with vΔ30/E315/
NS5654,655 (Figs. 3C, F, and I) or mock-inoculated controls (data not
shown). Taken together, vΔ30/E315/NS5654,655 is highly attenuated
for virus-induced neuropathology compared to the parental TBEV/
DEN4 and TBEV/DEN4Δ30 viruses.n the brains of 3-week-old SCID mice following IP inoculation with 105 PFU of virus. On
mouse brain homogenate was determined by immunofocus assay on Vero cells. Mean
iﬁcantly different from remaining viruses (unpaired t test or one-way ANOVA followed
10 PFU/g) of the assay.
Fig. 3.Neuroinﬂammation in the brains of mice infected with TBEV/DEN4 (A, D, and G), TBEV/DEN4Δ30 (B, E, and H), or vΔ30/E315/NS5654,655 (C, F, and I). Representative images of
neuroinﬂammation in the brain onday 6 frommice IC inoculatedwith each virus are shown (from25 sections per brain of eachof threemice;H&E staining). The boxed areas inA–C (×20)
are shown inD–F at highermagniﬁcation (×40); G–I show the boxed areas in D–F at highermagniﬁcation (×100). Inﬂammatory foci are shown by arrows (D, E, G, and H) and the dashed
circle (G).Abbreviations:Cx—cortex; CA1—hippocampus;DG—dentate gyrus; Th—thalamus;Or—oriens layer of thehippocampus; Py—pyramidal layer of thehippocampus; Rad—radiatum
layer of the hippocampus.
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Since the development of efﬁcacious, live attenuated vaccines
requires a ﬁne balance between virus attenuation and immunogenic-
ity, obtaining a live attenuated virus vaccine against TBEV has been
difﬁcult. Previous live attenuated TBEV vaccine candidates have either
retained a substantial level of neurovirulence (e.g., LGT, TBEV/DEN4,
or TBEV/DEN4Δ30 viruses) or were weakly immunogenic against
wild-type TBEV (e.g., LGT/DEN4) (Gritsun et al., 2003; Maximova
et al., 2008; Wright et al., 2008). TBEV/DEN4 virus exhibits a marked
reduction of neuroinvasiveness in immunocompetent adult mice
(Pletnev et al., 1992, 1993); however, despite replacing ∼80% of theTBEV genome with the non-structural genes of non-neurotropic
mosquito-borne DEN4 virus, TBEV/DEN4 nevertheless maintains a
high level of neurovirulence in suckling mice, comparable to that of
wild-type TBEV strain Sofjin (Rumyantsev et al., 2006a). The level of
neurovirulence observed with TBEV/DEN4 was in marked contrast to
that of chimeric vaccines previously developed against TBEV (LGT/
DEN4) and WN virus (WN/DEN4), which are highly attenuated for
both neuroinvasiveness and neurovirulence (Pletnev and Men, 1998;
Pletnev et al., 2006). Furthermore, introduction of the Δ30 deletion
into TBEV/DEN4 does not result in a satisfactory level of attenuation
for suckling mice or rhesus monkeys (Maximova et al., 2008;
Rumyantsev et al., 2006a), despite its ability to attenuate SLE/DEN4,
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and/or humans, leading to the generation of excellent vaccine
candidates for the latter three viruses (Blaney et al., 2008; Durbin
et al., 2001, 2006a,b; Pletnev et al., 2006; Whitehead et al., 2003).
Although TBEV/DEN4Δ30 is less neuroinvasive in immunodeﬁcient
mice than TBEV/DEN4, it retains a high level of neurovirulence in both
suckling mice and non-human primates and was therefore rejected as
a candidate for evaluation in humans (Maximova et al., 2008;
Rumyantsev et al., 2006a).
In this study, the neurovirulence of TBEV/DEN4 and TBEV/DEN4Δ30
was reduced by introducing attenuating amino acid substitutions that
had previously been shown to restrict the replication of LGT or DEN4
virus in cell culture and in suckling mouse brain (Hanley et al., 2002;
Rumyantsev et al., 2006b). The selected mutations were an amino acid
substitution at position 315 in the structural E protein, a major
contributor for in vitro and in vivo attenuation of the attenuated LGT
virus strain E5-104 (Rumyantsev et al., 2006b), and a paired charge-to-
alanine mutation at positions 654 and 655 in the DEN4 virus NS5
polymerase that is ts and results in a greater than1000-fold reduction in
replication of DEN4 inmouse brain (Hanley et al., 2002). Since previous
ﬂavivirus vaccine studies have demonstrated that a ts phenotype in cell
culture and attenuation inmice are often associatedwith attenuation in
non-human primates and humans (Halstead and Tsai, 2004; Rumyant-
sev et al., 2006a,b; Wright et al., 2008), neurovirulent TBEV/DEN4 and
TBEV/DEN4Δ30 viruses were modiﬁed and tested to select a more
attenuated TBEV vaccine candidate for further evaluation.
Introduction of the E315, NS5654,655, and E315/NS5654,655 mutations
into either TBEV/DEN4 or TBEV/DEN4Δ30 resulted in a stepwise
attenuation of the virus, both in vitro and in vivo. Speciﬁcally, the E315,
NS5654,655, and E315/NS5654,655 substitutions demonstrated the low-
est, moderate, and greatest level of attenuation, respectively.
Furthermore, the level of attenuation observed by introducing the
E315 or NS5654,655 mutations into TBEV/DEN4Δ30 was greater than
the level observed in the TBEV/DEN4 backbone, indicating that the set
of three mutations (E315, NS5654,655, and Δ30) results in an additive
level of attenuation. The cumulative effect of attenuation has been
demonstrated for many viruses, including JE virus (Halstead and Tsai,
2004), LGT virus strains E5 and E5-104 (Pletnev and Men, 1998;
Rumyantsev et al., 2006b), and YF virus strains Asibi and 17D (Barrett,
1997). Addition of all three mutations resulted in a virus that was
highly attenuated in vitro, less neurovirulent in suckling mice (up to
487-fold reduction compared to TBEV/DEN4Δ30), poorly replicative
in suckling mouse brain (between 500- and 20,000-fold reduction
compared to TBEV/DEN4 and TBEV/DEN4Δ30 viruses), and non-
neuroinvasive in immunodeﬁcient mice.
Although the presence of adventitious mutations in the attenuated
TBEV/DEN4Δ30 derivatives makes it difﬁcult to assign an observed
attenuation phenotype to the presence of the introduced mutation(s),
we were able to examine the pattern of attenuation demonstrated by
the individual or combined mutations in both TBEV/DEN4 and TBEV/
DEN4Δ30. It was clear that NS5654,655 was more attenuating than E315,
and the combination of E315/NS5654,655 had an even greater attenuating
effect than the individual mutations. The similar pattern of attenuation
speciﬁed by these mutations in two separate genetic backgrounds
suggests that the engineered mutations, rather than the presence of
adventitious mutations, contributed substantially to the observed
attenuation of the TBEV/DEN4Δ30 mutant viruses for neurovirulence
and neuroinvasiveness. Furthermore, the engineered substitutions in
the TBEV/DEN4Δ30-derived viruses were genetically stable in the
brains of sucklingmice, whether introduced alone or in combination, as
reverse mutations at the engineered sites were not detected in any of
the 25 brain-derived virus genomes examined. Since two nucleotides
were changed to introduce Asp315 in E and four nucleotides were
changed to introduce Ala654Ala655 in NS5, the likelihood of genetic
reversion in thehost is considered to be low, underscoring the high level
of genetic stability of these engineered mutations in vivo.Interestingly, the E315 mutation (Lys→Asp) had only a moderate
effect on attenuation in our studieswith chimeric TBEV. E315 is found on
the lateral surface of domain III (ED3), which resembles an immuno-
globulin-like fold and is the putativeﬂavivirus receptor-binding domain
thought to affect virus tropism (Lindenbach et al., 2007). Therefore,
altering this region may potentially disrupt secondary or tertiary
structure of E and ED3. Although E315 is poorly conserved within the
mosquito-borne ﬂaviviruses, it is highly conserved within the tick-
borneﬂaviviruses, as all tick-borneﬂaviviruses analyzed contained a Lys
residue at this position. In addition, several substitutions that have been
shown to affect virulence have been identiﬁed near the E315 residue in
various ﬂaviviruses, including YF, WN, JE, LGT, and LI viruses
(Hurrelbrink and McMinn, 2003; Mandl, 2005). Many of these
mutations have resulted in viruses that exhibit altered neurovirulence
and neuroinvasive properties compared to their parental viruses, sug-
gesting that this region is important for virus virulence and attenuation.
These observations, along with those by Rumyantsev et al. (2006b), led
us tohypothesize that theaddition of a negatively charged residue (Asp)
for a positively charged residue (Lys) at E315 would attenuate TBEV/
DEN4. When the E315 mutation was introduced into TBEV/DEN4, it did
not restrict replication of the virus in cell culture. However, it conferred
an sp phenotype when introduced into TBEV/DEN4Δ30. Mutating E315
in TBEV/DEN4Δ30 reducedmouse neurovirulence 4-fold, increasedAST
by 4.9 days, and reduced replication in suckling mouse brains 25-fold.
These data indicate that the E315 mutation reduced the ability of the
virus to replicate systemically and within the CNS, conﬁrming a role of
E315 in virus tropism for the CNS.
NS5654,655 was more attenuating than E315 in vitro and in vivo.
Whereas the Δ30 or E315 mutation did not independently confer a ts
phenotype in vitro, the NS5654,655 mutation, alone or in combination
with Δ30, was restrictive for growth in neuronal and Vero cell cultures,
respectively, cell cultures at elevated temperatures; however, a greater
restriction was observed with vΔ30/NS5654,655 than with vNS5654,655.
Reduced in vitro replication of these viruses at higher temperatures
(including 37 °C) indicates that the polymerase may be less thermo-
stable and unable to replicate virus RNA efﬁciently, particularly in
neuronal cells. Although the exact mechanism by which the NS5654,655
mutation results in attenuation remains to be identiﬁed, this may
explain the observed restricted replication of NS5654,655 mutants in the
brains ofmice, which have a core body temperature of 37 °C. Consistent
with the results in vitro, suckling mice demonstrated a 20- to 41-fold
reduction of neurovirulence and approximately a 10-day delay in AST
when inoculated with either vNS5654,655 or vΔ30/NS5654,655 virus,
respectively, compared to the parental viruses. Furthermore, the
combined Δ30 and NS5654,655 mutations completely ablated virus
neuroinvasiveness and replication in the brains of immunodeﬁcient
mice, even following peripheral inoculation with a high dose of virus
(105 PFU). These data are consistent with previous studies in which the
NS5654,655 substitutions in DEN4 and SLE/DEN4 genomes result in
viruses with a ts phenotype in vitro and reduced mouse neurovirulence
(Blaney et al., 2008; Hanley et al., 2002). Thus, the lack of neuroinva-
siveness and restricted replication in the brains of infected mice also
suggest that viruses containing NS5654,655 replicate poorly in both the
periphery and CNS of the host.
NS5 is the most highly conserved ﬂavivirus protein due to its
methyltransferase and RNA-dependent RNA polymerase (RdRp) func-
tions (Lindenbach et al., 2007). Although the 654 and 655 residues are
found in the palm domain of the RdRp, they are not adjacent to the
active site of the RdRp. However, the NS5654,655 residues are highly
conserved, as sequence alignment analysis demonstrates that most
mosquito- and tick-borne ﬂaviviruses contain a Glu residue at NS5654
(only DEN4 virus contains an Asp residue at this position), and all
ﬂaviviruses contain an Arg residue at NS5655. It is unclear whether the
NS5654,655 mutation attenuates the virus by impairing polymerase
function at elevated temperatures, as mentioned above, or by other
mechanisms. For example, the NS5 protein has been implicated in
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particularly with type I interferon receptor signal inhibition for many
ﬂaviviruses (Diamond, 2009). Although the NS5 of DEN4 virus is unable
to suppress STAT1 signal transduction (Park et al., 2007), DEN virus NS5
has been shown to reduce the level of STAT2 phosphorylation and
nuclear translocation, resulting in IFN α/β antagonism (Ashour et al.,
2009; Jones et al., 2005; Mazzon et al., 2009). Additional studies should
be undertaken in order to determinewhether the NS5654,655, mutations
exert an effect on type I IFN signaling, especially since these mutations
are proximal to sequences essential for inhibition of type I IFN signaling
in LGT virus NS5 (Park et al., 2007).
In summary, we have generated a live attenuated vaccine candidate
against TBEV by introducing three sets of genetically stable attenuating
mutations into TBEV/DEN4. Our current lead vaccine candidate is vΔ30/
E315/NS5654,655, a virus thatwas highly attenuated for the CNS ofmice, as
demonstrated by a lack of neuroinvasiveness and virus-induced
histopathology, as well as a signiﬁcant reduction in neurovirulence.
Furthermore, this triple mutant virus replicates in sucklingmouse brains
to a level comparable to another live attenuated ﬂavivirus vaccine
candidate, WN/DEN4Δ30, currently being tested in humans (Pletnev
et al., 2006). However, despite restricted replication in the CNS, vΔ30/
E315/NS5654,655 replicates efﬁciently in Vero cells, which would permit
efﬁcient vaccinemanufacture. Taken together, these results indicate that
vΔ30/E315/NS5654,655 achieved a high level of attenuation for the CNS
and represents an improved live attenuated vaccine candidate. Further-
more, preliminary studies in mice suggest that the immunogenicity of
vΔ30/E315/NS5654,655 is comparable to that of TBEV/DEN4Δ30, a virus
that has already been tested in non-human primates and is able to
protect against TBEV/DEN4 infection (Rumyantsev et al.,
2006a); however, additional studies are underway to further analyze
its immunogenicity andefﬁcacy inmice andnon-humanprimates aswell
as the infectivity of this vaccine candidate for tick and mosquito vectors.
Materials and methods
Cell culture
Simian Vero cells (World Health Organization seed, passages 143–
149) were maintained in Opti-Pro Serum Free Medium (Invitrogen,
Carlsbad, CA), supplemented with 4 mM L-glutamine (Invitrogen).
Human neuroblastoma SH-SY5Y cells weremaintained in 1:1Minimal
Essential and F12 media (Invitrogen), supplemented with 10% heat-
inactivated FBS (BioWhittaker, Basel, Switzerland), whereas human
glioblastoma LN-18 cells (ATCC, Manassas, VA) were maintained in
Dulbecco's Modiﬁed Eagle Medium (DMEM) (Invitrogen), supplemen-
ted with 5% heat-inactivated FBS, 4 mM of L-glutamine, and 1.5 g/L
sodium bicarbonate (Invitrogen).
Construction of full-length cDNA clones and recovery of chimeric viruses
Chimeric TBEV/DEN4 virus contains the prM and E protein genes of
Far Eastern subtype TBEV strain Sofjin and the remaining sequence
derived from recombinant DEN4 virus, while chimeric TBEV/DEN4Δ30
virus contains an additional 30 nucleotide deletion (nucleotides 10478-
10507) within the 3′ NCR of the genome. Construction of both viruses
has been described previously (Pletnev et al., 1992; Rumyantsev et al.,
2006a). The full-length infectious cDNA clones of TBEV/DEN4 and
TBEV/DEN4Δ30 (GenBank accession numbers FJ828986 and FJ828987,
respectively) were used in these studies to generate recombinant
viruses containing amino acid substitutions Lys→Asp within the E
protein at residue 315 (E315) and/or AspArg→AlaAla within the NS5
protein at residues 654 and 655 (NS5654,655). Although an attenuating
positive-to-negative charged amino acid substitution (Lys315→Glu;
AAA→GAA codons)was originallymutated in the E protein gene of LGT
virus (Rumyantsev et al., 2006b), an Asp residue (GAC codon) was
introduced into TBEV/DEN4 and TBEV/DEN4Δ30 at this position. Thissubstitution was chosen since it would require two nucleotide
substitutions in the Asp codon to restore the Lys residue and would
serve to reduce potential reversion to the positively charged Lys residue
(AAA or AAG codons).
DNA fragments encompassing either DEN4 virus- or TBEV-speciﬁc
sequences were sub-cloned into the pUC18 vector and each amino
acid substitution was introduced through site-directed mutagenesis,
as previously described (Hanley et al., 2002; Rumyantsev et al.,
2006b). Mutagenic primers introducing Asp (codon GAC) at amino
acid residue E315 (nucleotides 1893 and 1895) and AlaAla (codons
GCA and GCG) at amino acid residues NS5654,655 (nucleotides 9538-
9541) were used to engineer these mutations in pUC-TBEV and pUC-
DEN4c plasmid DNA, respectively. The pUC18-TBEV fragment
contained unique NheI and XhoI restriction sites that corresponded
to TBEV/DEN4 nucleotides 240-2361, while the pUC-DEN4c fragment
contained unique SacII and MluI sites that corresponded to TBEV/
DEN4 nucleotides 9334-10418. Fragments containing the desired
mutations were excised from pUC-TBEV or pUC-DENc by restriction
digest and introduced into the corresponding sites of the full-length
TBEV/DEN4 or TBEV/DEN4Δ30 infectious cDNA clones containing an
SP6 promoter (Pletnev et al., 1992). RNA transcripts derived from the
modiﬁed TBEV/DEN4 or TBEV/DEN4Δ30 cDNA cloneswere generated
by transcription with SP6 polymerase (EpiCentre, Madison, WI) after
linearization of the cDNA with Asp718 (Roche, Indianapolis, IN) and
subsequently transfected into Vero cells using Lipofectamine (Invi-
trogen). Since the mutations at positions E315 and NS5654,655
previously resulted in temperature sensitivity in either LGT or DEN4
virus, all mutant viruses were recovered and grown at 32 °C. The
recovered derivatives of TBEV/DEN4 and TBEV/DEN4Δ30 were
biologically cloned by two terminal dilutions and then ampliﬁed by
two passages in Vero cells before experimental virus stocks were
prepared. All experiments using TBEV/DEN4-derived viruses were
conducted in BSL-3 containment laboratories at the National
Institutes of Health, whereas all experiments using TBEV/DEN4Δ30-
derived viruses were conducted in BSL-2 laboratories.
To determine the titer of the chimeric TBEV/DEN4 viruses, conﬂuent
monolayers of Vero cells in 24- or 48-well plateswere infectedwith 10-
fold serial dilutions of virus, incubated at 37 °C for one hour, and then
were overlaid with Opti-MEM I containing 1%methylcellulose (Invitro-
gen), 2% heat-inactivated FBS, 4 mM L-glutamine, and 0.05 mg/ml of
gentamycin. After incubation for 6 days at 32 °C, the cells were ﬁxed for
20 min with 100% methanol, and plaques were visualized by immu-
nostainingwith TBEV-speciﬁc hyperimmunemouse asciticﬂuid (ATCC)
and peroxidase-labeled polymer conjugated to anti-mouse immuno-
globulin (Dako Co., Carpinteria, CA).
Recombinant plasmid DNA and cDNA genomes of the recovered
viruses were sequenced around the site of mutagenesis or in their
entirety to verify the presence of the introduced mutations within the
genome. Virus RNA was extracted from virus suspension using the
QiaAmp Viral RNA mini kit (Qiagen, Valencia, CA); one-step RT-PCR
was performed on the virus RNA using the Superscript One-Step kit
(Invitrogen) and DEN4 virus- or TBEV-speciﬁc primers. The nucleo-
tide consensus sequences of the virus genomes were determined
through direct sequence analysis of the PCR fragments on a 3730
Genetic Analyzer using TBEV- or DEN4 virus-speciﬁc primers in
BigDye terminator cycle sequencing reactions (Applied Biosystems,
Foster City, CA) and were analyzed using Sequencher 4.7 software
(Gene Codes Corporation, Ann Arbor, MI).
In vitro characterization of mutant viruses
Parental and mutant viruses were evaluated in a comparative study
for temperature sensitivity (ts) and small plaque (sp) phenotypes by
assessing virus titers at 32°, 35°, 37°, and 39 °C in simian kidney Vero,
human neuroblastoma SH-SY5Y, or human glioblastoma LN-18 cells.
The efﬁciency of plaque (EOP) formation was determined by infecting
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serially diluted virus for 1 h at 37 °C, after which Opti-MEM I overlay
containingmethylcellulose, FBS, and gentamycin was added. Cells were
incubated for 6 days at the assigned temperature and plaques were
visualized by immunostaining, as described above. A mutant was
deﬁned as having a ts phenotype if its shutoff temperature was≤39 °C.
The shutoff temperature for plaque formationwas deﬁned as the lowest
temperature at which the reduction in virus titer at a restrictive
temperature compared to its titer at 32 °Cwas 100-fold greater than the
reduction in parental virus titer between the same two temperatures.
Mutant viruses withmean plaque diameters that were≤50% of the size
of the parental TBEV/DEN4 or TBEV/DEN4Δ30 virus on Vero cells were
designated as having an sp phenotype.
Evaluation of mutant viruses in mice
Mice were handled according to Federal and NIAID Animal Care and
Use Committee regulations. To determine the neurovirulence of all
chimeric TBEV/DEN4 and TBEV/DEN4Δ30 viruses, 3-day-old Swiss
Webster mice (Taconic Farms, Germantown, NY), in litters of approx-
imately 10animals,were inoculatedwith10-fold serial dilutions of virus
via the intracerebral (IC) route. Three litters of mice per virus were
inoculated with 0.1, 1, or 10 PFU of TBEV/DEN4 or TBEV/DEN4Δ30,
whereas four litters of micewere inoculatedwith a dose ranging from 1
to 104 PFU of each mutant virus to determine their LD50 values. Mice
were monitored for morbidity and mortality up to 21 days post-
inoculation and the 50% lethal dose (LD50) was determined by the Reed
and Muench (1938) method. Moribund (paralyzed) mice were
humanely euthanized and scored as a lethality. Signiﬁcant differences
between LD50 levels were determined by using the nominal logistic ﬁt
for survival (pb0.05) (JMP V8.0 software, Cary, NC).
Further studies were undertaken in litters of 5-day-old suckling
Swiss Webster mice to investigate the replication kinetics of TBEV/
DEN4, TBEV/DEN4Δ30, or theirmutantderivatives inmouse brain.Mice
were inoculated IC with 103 PFU of virus and brains from at least three
mice per group were harvested every other day, up to day 21, as
described previously (Blaney et al., 2008; Pletnev et al., 2006). Mouse
brains were individually homogenized as a 10% solution (w/v) using
Hank's balanced salt solution (Invitrogen) supplemented with 7.5%
sucrose, 5 mM sodium glutamate, 0.05 mg/ml ciproﬂoxacin (Bayer,
Wayne, NJ), 0.06 mg/ml clindamycin (Pharmacia & Upjohn, New York,
NY), and 0.0025 mg/ml amphotericin B (Quality Biologicals, Gaithers-
burg,MD). Brain suspensionswere clariﬁedby low-speedcentrifugation
and frozen at −80 °C until use. Virus titers in brain suspensions were
quantitated by titration in Vero cells, as described above. Signiﬁcant
differences between viruses on eachdaywere determined byunpaired t
tests or one-way ANOVA followed by Tukey post hoc tests (pb0.05)
(GraphPad Prism 5 software, La Jolla, CA). To investigate the stability of
the engineered mutations within the chimeric viruses after their
replication in the brain, virus RNA was extracted from brain homo-
genates obtained on the last days they were positive for virus and
consensus sequences of the genomic regions encompassing the
engineered mutations from each group were directly determined.
To investigate the neuroinvasive phenotype of TBEV/DEN4, TBEV/
DEN4Δ30, and its derivatives, two sets of studies were performed
in 3-week-old SCID mice (ICRSC-M; Taconic Farms). To measure
neuroinvasiveness, 10 mice were inoculated IP with 105 PFU of TBEV/
DEN4 virus, while separate groups of 33 to 56 mice were inoculated IP
with 105 PFU of TBEV/DEN4Δ30 virus or its derivatives. Mice were
observed for 49 days for signs of morbidity typical of CNS involve-
ment, including paralysis. Moribund mice were humanely euthanized
upon signs neurologic disease. Kaplan–Meier survival curves followed
by Tukey post hoc tests were performed for statistical analysis
(pb0.05) (GraphPad Prism 5 software). Separately, groups of 35
SCID mice were inoculated IP with 105 PFU of TBEV/DEN4 or TBEV/
DEN4Δ30 virus, and the brains of three mice per group wereharvested on odd days, for 21 days, to assess the level of virus
replication. In addition, SCID mice in groups of 12 were inoculated IP
with 105 PFU of TBEV/DEN4Δ30-derivedmutant viruses. The brains of
three mice from each of these groups were harvested on days 13, 15,
17, and 19 to assess the level of virus replication as described above.
The signiﬁcance of viral replication on each day was determined by
unpaired t tests or one-way ANOVA followed by Tukey post hoc tests
(pb0.05) (GraphPad Prism 5 software).
Histopathological analysis of brains of mice infected with mutant viruses
To investigate virus-induced pathology of the viruses in brains,
3-week-old female C57BL/6 mice (Taconic Farms) in groups of
three were inoculated IC with 104 PFU of either TBEV/DEN4,
TBEV/DEN4Δ30, or vΔ30/E315/NS5654,655, whereas three control
mice were mock inoculated with Leibovitz's L-15 medium
(Invitrogen). All mice were observed daily and euthanized on
day 6, when TBEV/DEN4-infected mice developed paralysis. Mice
were euthanized and perfused transcardially with PBS, and each
mouse brain was dissected sagittally. The left hemisphere was
frozen and stored at −80 °C for virus quantitation as described
above. The right hemisphere was ﬁxed in 4% paraformaldehyde for
72 h and processed according to standard histological methods.
Twenty-ﬁve sections (30 μm thick) from each hemisphere were
stained with hematoxylin and eosin (H&E) and analyzed for the
presence and severity of virus-induced histopathology.
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